{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T11:19:15Z","timestamp":1793272755438,"version":"4.5.0"},"reference-count":24,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,3,1]]},"abstract":"<jats:p>This 2-part, double-blind, placebo-controlled study was conducted to determine the safety and efficacy of etoricoxib, a COX-2 selective inhibitor, for the treatment of hemophilic arthropathy. In part 1 (6 weeks), 102 patients (\u2265 12 years old) with hemophilic arthropathy were randomized to receive 90 mg etoricoxib once daily or placebo (1:1 ratio). In part 2 (6 months), 51 patients taking placebo in part 1 were randomized to receive 90 mg etoricoxib or 25 mg rofecoxib once daily; patients taking etoricoxib in part 1 continued the same treatment. Efficacy end points included Patient Assessment of Arthropathy Pain, Patient Global Assessment of Arthropathy Disease Status, and Investigator Global Assessment of Arthropathy Disease Status. Safety was evaluated at each study visit. Etoricoxib provided significant improvement in all end points versus placebo (P &lt; .001). Fewer patients taking etoricoxib discontinued due to a lack of efficacy versus placebo (P = .048). During part 2, efficacy was maintained; etoricoxib and rofecoxib demonstrated similar results. The most common adverse experiences were upper respiratory infection and headache. The incidence of joint bleeding during part 1 was similar between etoricoxib (66.7%) and placebo (72.6%) and during part 2 between etoricoxib (77.0%) and rofecoxib (78.9%). We conclude that etoricoxib provided superior efficacy versus placebo for the treatment of hemophilic arthropathy and was generally safe and well tolerated.<\/jats:p>","DOI":"10.1182\/blood-2004-09-3501","type":"journal-article","created":{"date-parts":[[2005,11,16]],"date-time":"2005-11-16T03:18:17Z","timestamp":1132111097000},"page":"1785-1790","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":43,"title":["Evaluation of the efficacy and safety of etoricoxib in the treatment of hemophilic arthropathy"],"prefix":"10.1182","volume":"107","author":[{"given":"Christos","family":"Tsoukas","sequence":"first","affiliation":[{"name":"From the McGill University Health Centre, Montreal, QC, Canada; Penn State Hershey Medical Center, Hershey, PA; and Merck Research Laboratories, Rahway, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Elaine","family":"Eyster","sequence":"additional","affiliation":[{"name":"From the McGill University Health Centre, Montreal, QC, Canada; Penn State Hershey Medical Center, Hershey, PA; and Merck Research Laboratories, Rahway, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumiko","family":"Shingo","sequence":"additional","affiliation":[{"name":"From the McGill University Health Centre, Montreal, QC, Canada; Penn State Hershey Medical Center, Hershey, PA; and Merck Research Laboratories, Rahway, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh","family":"Mukhopadhyay","sequence":"additional","affiliation":[{"name":"From the McGill University Health Centre, Montreal, QC, Canada; Penn State Hershey Medical Center, Hershey, PA; and Merck Research Laboratories, Rahway, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen M.","family":"Giallella","sequence":"additional","affiliation":[{"name":"From the McGill University Health Centre, Montreal, QC, Canada; Penn State Hershey Medical Center, Hershey, PA; and Merck Research Laboratories, Rahway, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean P.","family":"Curtis","sequence":"additional","affiliation":[{"name":"From the McGill University Health Centre, Montreal, QC, Canada; Penn State Hershey Medical Center, Hershey, PA; and Merck Research Laboratories, Rahway, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alise S.","family":"Reicin","sequence":"additional","affiliation":[{"name":"From the McGill University Health Centre, Montreal, QC, Canada; Penn State Hershey Medical Center, Hershey, PA; and Merck Research Laboratories, Rahway, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agustin","family":"Melian","sequence":"additional","affiliation":[{"name":"From the McGill University Health Centre, Montreal, QC, Canada; Penn State Hershey Medical Center, Hershey, PA; and Merck Research Laboratories, Rahway, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111816251326900_REF1","doi-asserted-by":"crossref","unstructured":"Mannucci PM, Tuddenham EG. The hemophilias\u2014-from royal genes to gene therapy. N Engl J Med. 2001;344: 1773-1779.","DOI":"10.1056\/NEJM200106073442307"},{"key":"2019111816251326900_REF2","unstructured":"Upchurch KS, Brettler DB. Hemophilic Arthropathy. In: Buddy S, Harris ED, Sledge CB, eds. Kelley's Textbook of Rheumatology. Philadelphia, PA: WB Saunders; 2004: 1567-1574."},{"key":"2019111816251326900_REF3","doi-asserted-by":"crossref","unstructured":"Berntorp E, Astermark J, Bjorkman S, et al. Consensus perspectives on prophylactic therapy for haemophilia: summary statement. Haemophilia. 2003;9(suppl 1): 1-4.","DOI":"10.1046\/j.1365-2516.9.s1.17.x"},{"key":"2019111816251326900_REF4","doi-asserted-by":"crossref","unstructured":"Luck JV Jr, Silva M, Rodriguez-Merchan EC, et al. Hemophilic arthropathy. J Am Acad Orthop Surg. 2004;12: 234-245.","DOI":"10.5435\/00124635-200407000-00004"},{"key":"2019111816251326900_REF5","doi-asserted-by":"crossref","unstructured":"Roosendaal G, Lafeber FP. Blood-induced joint damage in hemophilia. Semin Thromb Hemost. 2003;29: 37-42.","DOI":"10.1055\/s-2003-37938"},{"key":"2019111816251326900_REF6","doi-asserted-by":"crossref","unstructured":"Cherny NL. Opioid analgesics\u2014comparative features and prescribing guidelines. Drugs. 1996;51: 713-737.","DOI":"10.2165\/00003495-199651050-00002"},{"key":"2019111816251326900_REF7","doi-asserted-by":"crossref","unstructured":"Cagnoni PJ, Aledort L. Gastrointestinal bleeding in hemophilia as a complication of the use of over the counter non-steroidal anti-inflammatory drugs. Am J Hematol. 1994;47: 336-337.","DOI":"10.1002\/ajh.2830470425"},{"key":"2019111816251326900_REF8","doi-asserted-by":"crossref","unstructured":"Hilgartner MW. Current treatment of hemophilic arthropathy. Curr Opin Pediatr. 2002;14: 46-49.","DOI":"10.1097\/00008480-200202000-00008"},{"key":"2019111816251326900_REF9","doi-asserted-by":"crossref","unstructured":"Dallob A, Hawkey CJ, Greenberg H, et al. Characterization of etoricoxib, a novel, selective COX-2 inhibitor. J Clin Pharmacol. 2003;43: 573-585.","DOI":"10.1177\/0091270003253703"},{"key":"2019111816251326900_REF10","doi-asserted-by":"crossref","unstructured":"Ramey D, Watson DJ, Yu C, et al. The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis. Curr Med Res Opin. 2005;21: 715-722.","DOI":"10.1185\/030079905X43686"},{"key":"2019111816251326900_REF11","doi-asserted-by":"crossref","unstructured":"Laine L, Connors LG, Reicin A, et al. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology. 2003;124: 288-292.","DOI":"10.1053\/gast.2003.50054"},{"key":"2019111816251326900_REF12","doi-asserted-by":"crossref","unstructured":"Matsumoto AK, Cavanaugh PF Jr. Etoricoxib. Drugs Today (Barc). 2004;40: 395-414.","DOI":"10.1358\/dot.2004.40.5.850488"},{"key":"2019111816251326900_REF13","unstructured":"Forbes CD, Barr RD, Prentice CR, Douglas AS. Gastrointestinal bleeding in haemophilia. Q J Med. 1973;42: 503-511."},{"key":"2019111816251326900_REF14","unstructured":"Singh G, Rosen RD. NSAID induced gastrointestinal complications: the ARAMIS perspective\u20141997. Arthritis, Rheumatism, and Aging Medical Information System. J Rheumatol Suppl. 1998;51: 8-16."},{"key":"2019111816251326900_REF15","doi-asserted-by":"crossref","unstructured":"Hunt RH, Harper S, Callegari P, et al. Complementary studies of the gastrointestinal safety of the cyclo-oxygenase-2-selective inhibitor etoricoxib. Aliment Pharmacol Ther. 2003;17: 201-210.","DOI":"10.1046\/j.1365-2036.2003.01407.x"},{"key":"2019111816251326900_REF16","doi-asserted-by":"crossref","unstructured":"Brater DC, Harris C, Redfern JS, Gertz BJ. Renal effects of cox-2-selective inhibitors. Am J Nephrol. 2001;21: 1-15.","DOI":"10.1159\/000046212"},{"key":"2019111816251326900_REF17","doi-asserted-by":"crossref","unstructured":"Birbara CA, Puopolo AD, Munoz DR, et al. Treatment of chronic low back pain with etoricoxib, a new cyclo-oxygenase-2 selective inhibitor: improvement in pain and disability-a randomized, placebo-controlled, 3-month trial. J Pain. 2003;4: 307-315.","DOI":"10.1016\/S1526-5900(03)00633-3"},{"key":"2019111816251326900_REF18","doi-asserted-by":"crossref","unstructured":"Ruperto N, Nikishina I, Pachanov ED, et al. A randomized, double-blind clinical trial of two doses of meloxicam compared with naproxen in children with juvenile idiopathic arthritis: short- and long-term efficacy and safety results. Arthritis Rheum. 2005;52: 563-572.","DOI":"10.1002\/art.20860"},{"key":"2019111816251326900_REF19","doi-asserted-by":"crossref","unstructured":"Skjelbred P, Lokken P. Paracetamol versus placebo: effects on post-operative course. Eur J Clin Pharmacol. 1979;15: 27-33.","DOI":"10.1007\/BF00563555"},{"key":"2019111816251326900_REF20","doi-asserted-by":"crossref","unstructured":"Bertin P, Keddad K, Jolivet-Landreau I. Acetaminophen as symptomatic treatment of pain from osteoarthritis. Joint Bone Spine. 2004;71: 266-274.","DOI":"10.1016\/j.jbspin.2003.09.010"},{"key":"2019111816251326900_REF21","doi-asserted-by":"crossref","unstructured":"Boardman PL, Hart FD. Clinical measurement of the anti-inflammatory effects of salicylates in rheumatoid arthritis. Br Med J. 1967;4: 264-268.","DOI":"10.1136\/bmj.4.5574.264"},{"key":"2019111816251326900_REF22","doi-asserted-by":"crossref","unstructured":"Ring EF, Collins AJ, Bacon PA, Cosh JA. Quantitation of thermography in arthritis using multi-isothermal analysis, II: effect of nonsteroidal anti-inflammatory therapy on the thermographic index. Ann Rheum Dis. 1974;33: 353-356.","DOI":"10.1136\/ard.33.4.353"},{"key":"2019111816251326900_REF23","doi-asserted-by":"crossref","unstructured":"Pincus T, Koch GG, Sokka T, et al. A randomized, double-blind, crossover clinical trial of diclofenac plus misoprostol versus acetaminophen in patients with osteoarthritis of the hip or knee. Arthritis Rheum. 2001;44: 1587-1598.","DOI":"10.1002\/1529-0131(200107)44:7<1587::AID-ART282>3.0.CO;2-X"},{"key":"2019111816251326900_REF24","doi-asserted-by":"crossref","unstructured":"Gottesdiener K, Schnitzer T, Fisher C, et al. Results of a randomized, dose-ranging trial of etoricoxib in patients with osteoarthritis. Rheumatol. 2002:41: 1052-1061.","DOI":"10.1093\/rheumatology\/41.9.1052"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/107\/5\/1785\/468790\/zh800506001785.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/107\/5\/1785\/468790\/zh800506001785.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T21:25:28Z","timestamp":1574112328000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/107\/5\/1785\/133377\/Evaluation-of-the-efficacy-and-safety-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3,1]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006,3,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2004-09-3501","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,3,1]]}}}